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Objectives The authors sought to investigate the gene and protein expression in Lamin A/C (LMNA)-mutated dilated cardio-
laminopathy (DCM) patients (DCMLMNAMut) versus LMNA-wild-type DCM (DCMLMNAWT), and normal controls
(CTRLLMNAWT).
Background Dilated cardiolaminopathies are clinically characterized by high arrhythmogenic risk and caused by LMNA muta-
tions. Little is known regarding quantitative gene expression (QGE) of the LMNA gene in blood and myocardium,
as well as regarding myocardial expression of the lamin A/C protein.
Methods Using the comparative CT method, we evaluated the QGE of LMNA (QGELMNA) in peripheral blood and myocar-
dial RNA from carriers of LMNA mutations, versus blood and myocardial samples from DCMLMNAWT patients and
CTRLLMNAWT individuals. After generating reference values in normal controls, QGELMNA was performed in 311
consecutive patients and relatives, blind to genotype, to assess the predictive value of QGELMNA for the identifica-
tion of mutation carriers. In parallel, Lamin A/C was investigated in myocardial samples from DCMLMNAMut
versus DCMLMNAWT versus normal hearts (CTRLLMNAWT).
Results LMNA was significantly underexpressed in mRNA from peripheral blood and myocardium of DCMLMNAMut patients
versus DCMLMNAWT and CTRLLMNAWT. In 311 individuals, blind to genotype, the QGELMNA showed 100% sensitivity
and 87% specificity as a predictor of LMNA mutations. The receiver-operating characteristic curve analysis
yielded an area under the curve of 0.957 (p  0.001). Loss of protein in cardiomyocytes’ nuclei was docu-
mented in DCMLMNAMut patients.
Conclusions The reduced expression of LMNA gene in blood is a novel potential predictive biomarker for dilated cardiolamin-
opathies with parallel loss of protein expression in cardiomyocyte nuclei. (J Am Coll Cardiol 2012;60:1916–20)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.059dDilated cardiomyopathy (DCM) is a primary myocardial
disease with heterogeneous etiology, wherein genetic defects
are found in up to 48% of DCM cases (1). Lamin A/C
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accepted May 28, 2012.(LMNA) mutations occur in approximately 8% of familial
cases (2); the most common cardiac phenotype associated
with LMNA defects comprises DCM with conduction
disease (80%), high arrhythmogenic risk, and progression to
end-stage heart failure (3–5). Haploinsufficiency is a major
mechanism of myocardial damage in Lmna/ mouse
models (6). In human laminopathy, the expression of the
protein in the nuclear membrane of cardiac and skeletal
myocytes may either be reduced or remain normal (4,7).
Although quantitative gene expression (QGE) in periph-
eral blood has been suggested as a promising molecular
signature of DCM (8), only scattered data exist of the
mutated LMNA gene (QGELMNA) in patients with car-
iolaminopathy (9).
To investigate the expression of lamin A/C protein and
GELMNA as well as its potential diagnostic contribution to
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November 6, 2012:1916–20 Gene and Protein Expression in Cardiolaminopathiesthe clinical work-up of cardiomyopathy, we determined
immunohistochemical expression of the lamin A/C protein
in the myocardium and QGELMNA in RNA from myocar-
dial tissue and peripheral blood samples of DCM patients
with LMNA mutations.
Methods
The study was designed to measure LMNA gene expression in
DCM patients with known LMNAmutations (DCMLMNAMut)
n comparison with both DCM patients with wild-type
MNA (DCMLMNAWT) and healthy control subjects
(CTRLLMNAWT) (Online Fig. 1). Methods used for genetic
testing of LMNA and for QGELMNA at both the myocardial and
he peripheral blood levels are detailed in the Online Methods.
In the first part of the study, we established the normal
GELMNA values in 115 CTRLLMNAWT subjects for the
evaluation of 96 DCMLMNAWT and 67 DCMLMNAMUT pa-
ients. In the second part, we aimed to assess the value of the
Figure 1 QGELMNA Study
(A to C) First part of the study: QGELMNA (2Ct  SEM) in total RNA from periphe
els did not vary in patients with different types of mutations, and (C) with mutatio
Second part of the study: receiver-operating characteristic (ROC) curve analysis fo
threshold value with the highest sensitivity, the area under the curve (AUC) was 0
sus CTRLLMNAWT. CTRL  normal control; DCM  dilated cardiolaminopathy; PTC GELMNA assay for predicting
LMNA mutations in 311 individu-
als, both DCM probands and rela-
tives, blinded to genotype. Online
Table 1 summarizes the mutations,
the number of patients that were
included in the first study, and the
number of mutated patients and
healthy carriers that were included in
the second study. In the third part,
directed at myocardial tissue, we also
performed QGELMNA in endomyo-
ardial biopsy (EMB) samples ob-
ained from 25 DCMLMNAMUT
prospective heart transplant re-
cipients and compared them with 20 CTRLLMNAWT endo-
yocardial biopsies obtained from donor hearts before
ransplantation. In addition to QGELMNA, using anti-lamin
od of 67 DCMLMNAMut, 96 DCMLMNAWT, and 115 CTRLLMNAWT. (B) QGELMNA lev-
alized upstream or downstream of the nuclear localizing sequence (NLS). (D)
GELMNA in the peripheral blood RNA from the 311 consecutive cases. At the
 0.001). (E) Third part of the study: myocardial samples of DCMLMNAMut ver-
ature termination codon; QGE  quantitative gene expression.
Abbreviations
and Acronyms
DCM  dilated
cardiomyopathy
EMB  endomyocardial
biopsy
NLS  nuclear localizing
sequence
PTC  premature
termination codon
QGE  quantitative gene
expression
ROC  receiver-operating
characteristicral blo
ns loc
r the Q
.957 (p
prem
au
a
p
t
S
o
t
T
t
p
s

C
r
w
R
P
l
Q
1
(
p
0
D
s
(
C
b
c
m
m
U
c
b
o
3
1918 Narula et al. JACC Vol. 60, No. 19, 2012
Gene and Protein Expression in Cardiolaminopathies November 6, 2012:1916–20A/C antibodies (4), the protein expression was determined
in 25 myocardial samples of patients with DCMLMNAMut,
20 DCMLMNAWT, and 20 CTRLLMNAWT. Western blot
nalysis was undertaken in 12 DCMLMNAMut and 9 control
heart samples with wild-type LMNA (Online Methods).
We managed to collect appropriate samples for RNA in 22
patients with known laminopathy on 2 different occasions to
assess whether the QGELMNA would change during follow-
p. The study complies with the Declaration of Helsinki
nd was approved by the local ethics committee. All study
articipants provided written informed consent for genetic
esting and anonymous data publication for scientific purposes.
tatistical analysis. For QGELMNA, relative quantification
f the LMNA RNA at each time point was determined using
he comparative CT method (10) (Online Materials).
he Kruskal-Wallis nonparametric test was used for mul-
iple comparisons, using Mann-Whitney rank sum test with
ost hoc Bonferroni correction. The Mann-Whitney rank
um test was used for nonmultiple comparisons. A p value
0.05 was considered significant. Stata 10.1 (StataCorp,
ollege Station, Texas) was used for computation. The
eceiver-operating characteristic (ROC) curve analysis (11)
as performed in the 311 cases blind to mutations.
esults
eripheral blood study: LMNA mRNA levels in known
aminopathy and controls. EXPRESSION OF LMNA mRNA
LEVELS IN PATIENTS WITH KNOWN DCMLMNAMUT. The
GELMNA referral value in CTRLLMNAWT individuals was
.92. LMNA was underexpressed by 30% in DCMLMNAMut
patients as compared with CTRLLMNAWT individuals
2Ct SEM 1.32 0.10 vs. 1.92 0.18, respectively;
 0.007) (Fig. 1A), and by 26% (2Ct SEM 1.32
.10 vs. 1.76  0.16; p  0.02) as compared with
CMLMNAWT patients. Values observed in DCMLMNAWT
versus CTRLLMNAWT were not significantly different (p 0.71).
LMNA mRNA LEVELS AND MUTATION TYPE. Comparative
evaluation of LMNA mRNA levels among groups of pa-
tients with different types of LMNA mutations (missense,
n  37; in-frame insertion/deletion, n  7; nonsense
mutations and frameshift insertions/deletions, predicting a
premature termination codon [PTC] and truncated lamin
A/C protein [n  12]; and splice site [n  11]) did not
demonstrate significant differences (p  0.93) (Fig. 1B).
LMNA mRNA LEVELS AND MUTATION POSITION. QGELMNA
did not differ in carriers of mutations up- and downstream
of the nuclear localizing sequence (NLS) (2Ct  SEM 
1.35  0.10 and 1.18  0.33; p  0.75), all showing
ignificantly lower levels when compared with controls
upstream NLS 2Ct  SEM  1.35  0.10 vs.
CTRLLMNAWT  1.92  0.18; p  0.01) and 39%
(downstream NLS 2Ct  SEM  1.18  0.33 vs.
TRLLMNAWT  1.92  0.18; p  0.007), respectively
(Fig. 1C). sPeripheral blood study: LMNA mRNA levels in 311
consecutive patients and relatives, blinded to genotype.
The ROC analysis (Fig. 1D) yielded an area under the curve
of 0.957 (95% confidence interval: 0.928 to 0.977) with
significance level p  0.001, confirming the QGELMNA
value as a robust possible predictor of mutation presence.
On the basis of the sensitivity and specificity of the assay, we
tested 3 possible ratios as threshold values: 0.60, 0.70, and
0.75 (Table 1). Since our major aim was to predict LMNA
mutations, we selected the threshold value of 0.75 that
showed the highest sensitivity (100%) but the lowest spec-
ificity (87%). Using this threshold, the QGELMNA assay
predicted not only all mutation carriers, but also 30 patients/
individuals with the wild-type LMNA gene. (Online Table 2
lists QGELMNA data in the 311 samples, blind to genotype
efore QGELMNA.)
In the 22 LMNA mutation carriers with at least 2
samples obtained at different intervals (2.18  1.43 years),
LMNA gene expression showed a trend to decrease with
time (Online Table 3). A possible future relevance of com-
parative evaluation over time is related to the potential use of
QGELMNA for monitoring the evolution of the disease or
correlation with functional data or medical treatment.
Myocardial tissue studies. PATHOLOGICAL FEATURES.
EMB of DCMLMNAMut patients revealed prominent nuclear
hanges, including irregularities of the morphological profile of
yocyte nuclei and increased chromatin density, multifocal
yofibrillar loss, and fibrosis of variable extent and severity.
ltrastructural study demonstrated severe changes in the nu-
lear membranes with blebs, pore clustering, nuclear microtu-
ular structures, and pseudoinclusions (Fig. 2G).
LAMIN A/C IMMUNOSTAIN AND WESTERN BLOT. The EMBs
f CTRLLMNAWT and of DCMLMNAWT patients demon-
Sensitivity and Specificity of QGELMNA in11 Consecutive individuals Blinded to GenotypeTable 1 Sensitiv ty and Specificity of QGE
LMNA in
311 Consecutive individuals Blinded to Genotype
Threshold % Mutation  Mutation  Total
Threshold value 0.75
0.75 72 30 102
0.75 0 209 209
Total for threshold 0.75 72 239 311
Sensitivity 100
Specificity 87
Threshold value 0.7
0.70 68 24 92
0.70 4 215 219
Total for threshold 0.7 72 239 311
Sensitivity 94
Specificity 90
Threshold value 0.6
0.60 56 17 73
0.60 16 222 238
Total for threshold 0.6 72 239 311
Sensitivity 78
Specificity 93trated homogeneous protein localization throughout the
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November 6, 2012:1916–20 Gene and Protein Expression in Cardiolaminopathiesnuclear membrane of the nuclei of myocytes (Figs. 2A and 2B).
yocytes of DCMLMNAMut patients exhibited variable loss
of lamin A/C expression (Figs. 2C to 2F), whereas inter-
stitial and endothelial cells showed normal expression of the
protein. Decreased protein expression was confirmed by
Western blot analysis (Fig. 2H).
LMNA GENE EXPRESSION IN MYOCARDIAL TISSUE. There
as 71% underexpression of LMNA in the myocardial samples of
DCMLMNAMut patients (2Ct  SEM  41.56  12.06) as
ompared with myocardium from CTRLLMNAWT (2Ct 
EM 143.72 2.59) with a ratio of mutated versus wild type
of 29% (p  0.001) (Fig. 1E).
iscussion
he present study documents that DCMLMNAMut patients and
healthy mutation carriers show decreased expression of the
mutated gene in the mRNA in peripheral blood samples as
well as the affected myocardium when compared with both
normal controls and DCM patients with wild-type LMNA. In
addition, the LMNA protein is underexpressed at the nuclear
Figure 2 Lamin A/C Expression Studies
(A to F) Immunostain with anti-Lamin A/C antibodies: (A) normal nuclear express
myocyte nuclei but preserved nuclear immunostain. (C to F) Loss of immunolabel
(C) IVS2-1GA; (D) p.(Glu111X); (E) p.(Leu526_Arg527 insProAlafsX24); and (F)
LMNA p.(Arg225X) mutation, showing the prominent structural changes in myocyte
obtained from hearts excised at transplantation. The decreased expression of the
molecular weight (kilodaltons); WT  wild type; other abbreviations as in Figure 1.level in the cardiac myocytes of cardiolaminopathy patients.The QGELMNA assay is a potential biomarker for cardio-
aminopathies. LMNA gene expression decreases indepen-
ently of mutation type in myocardial RNA. Although to a
ower extent, a similar decrease is observed in the corre-
ponding peripheral blood mRNA. Given the lower cost
nd the ease of performing the QGE compared with the
enetic test, it could constitute a pre-genetic assay for
uiding LMNA gene testing, which is the diagnostic gold
tandard. However, whereas the QGELMNA assay for the
threshold ratio value of 0.75 recognized all mutated pa-
tients, it also showed a false-positive result in 30 patients
with the wild-type LMNA gene.
The decreased gene and protein expression confirms haplo-
insufficiency as major disease mechanism in humans. The
loss of lamin A/C in cardiac myocytes in vivo supports the
haploinsufficiency mechanism previously shown in experi-
mental models (6). Actively cycling cell types, including
endothelial and interstitial cells, displayed normal LMNA
immunostaining as compared with the gradual decrease in
type-A lamins in the terminally differentiated cardiac myo-
cytes. Low LMNA mRNA levels in the terminally differ-
entiated, quiescent cells preclude the possibility of increased
Lamin A/C in CTRLLMNAWT; (B) DCMLMNAWT showing abnormal morphology of the
uclei of myocytes from DCMLMNAMut patients harboring the following mutations:
90Trp). (G) Electron micrograph of a cardiomyocyte in a patient harboring the
lei with pseudoinclusions (arrows). (H) Western blot: myocardial samples
n shows little variations in carriers of different LMNA mutations. MW(KD) ion of
ing in n
p.(Arg1
s’ nuc
proteiLMNA mRNA translation to stabilize the degradation rate,
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Gene and Protein Expression in Cardiolaminopathies November 6, 2012:1916–20whereas the increased mRNA levels in cycling cells moder-
ately compensates for the progressive loss of protein (12).
In carriers of splice site and PTC mutations, the low
levels of LMNA mRNA are likely explained by the rapid
degradation of transcripts with PTC mutations by nonsense
mediated decay as suggested in a family with dilated
cardiolaminopathy harboring the p.Arg321X LMNA muta-
tion (13). In carriers of missense LMNA mutations, the low
levels of LMNA mRNA are likely due to modifications of
the position and compaction of chromatin (14). The teth-
ering of mammalian genes to the nuclear lamina leads to
transcriptional repression possibly as a result of separation
from the RNA Polymerase II machinery or formation of a
repressive chromatin structure (9). The key role of lamins in
the structure and function of nuclei suggests that gene-
specific and genome-wide chromatin rearrangements may
contribute to molecular mechanisms of pathology observed
in patients with LMNA mutations (15).
Decreased expression of Lamin A/C in myocardial
samples. Lamin A/C protein expression is decreased in
myocyte nuclei of affected hearts, independently of mutation
type. The underexpression of the protein in vivo has been
previously shown in the myocardium of patients with
dilated cardiolaminopathy (4), and is now confirmed, thus
being a diagnostic contributor if EMB is performed. The
decreased amount of lamin A/C is also confirmed by
Western blot analysis of myocardial samples in which
immunohistochemistry showed selective loss of protein in
the nuclei of cardiac myocytes.
Study limitations. Since the inclusion criterion for the
QGELMNA in the 311 cases blind to genotype was consecutive
nrollment, the series included both patients and healthy relatives.
his may be a limitation for the nonindependence of observations.
onclusions
oth decreased expression of LMNA gene and variable loss
f lamin A/C immunostain in EMB may contribute to the
iagnostic algorithm in cardiolaminopathy. In particular,
he reduced mRNA expression levels in blood offers to be a
otential biomarker in patients for monitoring of the
GELMNA in LMNA mutation carriers.
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APPENDIX
For an expanded methods and supplementary tables and figure, please see
the online version of this paper.
